Research Paper Volume 13, Issue 1 pp 1458—1472

CHIP protects against MPP+/MPTP-induced damage by regulating Drp1 in two models of Parkinson’s disease

Experimental design of in vivo experiment. (A) C57BL/6 wildtype mice were divided into three groups, 8-10 mice per group. At 6–8 weeks old, mice received equal dose of AAV or PBS injection intravenously via tail vein. 4 weeks later, mice were trained for behavioral tests including pole test, rotarod test and open-field test. Then animals were administered four intraperitoneal injections of MPTP (20 mg/kg) at 2 h intervals. Behavioral tests were conducted at 1st, 3rd, 5th and 7th days. After that, Mice were sacrificed for the continue experiment. (B) NES-CHIP mice and wildtype littermates were treated in the same way with the former animals except for not receiving injections.

Figure 5. Experimental design of in vivo experiment. (A) C57BL/6 wildtype mice were divided into three groups, 8-10 mice per group. At 6–8 weeks old, mice received equal dose of AAV or PBS injection intravenously via tail vein. 4 weeks later, mice were trained for behavioral tests including pole test, rotarod test and open-field test. Then animals were administered four intraperitoneal injections of MPTP (20 mg/kg) at 2 h intervals. Behavioral tests were conducted at 1st, 3rd, 5th and 7th days. After that, Mice were sacrificed for the continue experiment. (B) NES-CHIP mice and wildtype littermates were treated in the same way with the former animals except for not receiving injections.